OSTEOSARCOMA RECURRENT
Clinical trials for OSTEOSARCOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new OSTEOSARCOMA RECURRENT trials appear
Sign up with your email to follow new studies for OSTEOSARCOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for tough bone cancer
Disease control OngoingThis study tests a combination of two drugs, regorafenib and nivolumab, in people with osteosarcoma (a type of bone cancer) that has come back or not responded to treatment. The goal is to see if this combination can stop the cancer from growing longer than regorafenib alone. Abo…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE2 • Sponsor: Sarcoma Alliance for Research through Collaboration • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug combo aims to halt returning bone cancer
Disease control OngoingThis study tests whether two drugs, olaparib and ceralasertib, can help control osteosarcoma that has come back or not responded to treatment. It includes 63 people aged 12 to 40. The goal is to see if the combination can stop the cancer from growing for at least 4 months.
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Immunotherapy combo shows promise against returning bone cancer
Disease control OngoingThis study tests two immunotherapy drugs, nivolumab and azacitidine, in people whose osteosarcoma (a type of bone cancer) has come back and can be removed with surgery. The goal is to see if these drugs are safe and help keep the cancer from returning after surgery. About 21 adul…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 11, 2026 20:39 UTC